Stock analysts at Aegis initiated coverage on shares of Zogenix Inc. (NASDAQ:ZGNX) in a research note issued on Friday. The brokerage set a “buy” rating and a $28.00 price target on the stock. Aegis’ target price indicates a potential upside of 134.31% from the stock’s current price.

A number of other research firms have also commented on ZGNX. Zacks Investment Research upgraded shares of Zogenix from a “sell” rating to a “hold” rating in a research report on Saturday, August 13th. Brean Capital restated a “buy” rating and set a $28.00 price target on shares of Zogenix in a research report on Wednesday, September 21st. Finally, Leerink Swann reiterated an “outperform” rating and issued a $17.00 target price on shares of Zogenix in a research report on Tuesday, October 4th.

Shares of Zogenix (NASDAQ:ZGNX) opened at 11.95 on Friday. The firm’s market capitalization is $296.24 million. Zogenix has a one year low of $7.33 and a one year high of $16.56. The firm’s 50-day moving average price is $9.63 and its 200-day moving average price is $9.31.

Zogenix (NASDAQ:ZGNX) last released its quarterly earnings results on Monday, November 7th. The company reported ($0.69) EPS for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.27. The firm earned $6.57 million during the quarter, compared to analyst estimates of $3.10 million. Zogenix had a negative net margin of 229.93% and a negative return on equity of 38.11%. The business’s revenue for the quarter was down 28.0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.65) EPS. On average, equities analysts forecast that Zogenix will post ($2.71) earnings per share for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Gagnon Securities LLC bought a new position in shares of Zogenix during the second quarter valued at about $1,236,000. Blair William & Co. IL increased its stake in Zogenix by 239.1% in the second quarter. Blair William & Co. IL now owns 195,500 shares of the company’s stock valued at $529,000 after buying an additional 137,850 shares in the last quarter. Opaleye Management Inc. acquired a new stake in Zogenix during the first quarter valued at $2,218,000. Lombard Odier Asset Management USA Corp increased its stake in Zogenix by 2.8% in the second quarter. Lombard Odier Asset Management USA Corp now owns 651,418 shares of the company’s stock valued at $5,244,000 after buying an additional 17,916 shares in the last quarter. Finally, Landscape Capital Management L.L.C. increased its stake in Zogenix by 56.4% in the second quarter. Landscape Capital Management L.L.C. now owns 243,595 shares of the company’s stock valued at $1,961,000 after buying an additional 87,890 shares in the last quarter. Institutional investors own 85.23% of the company’s stock.

Zogenix Company Profile

Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders in requirement of treatment alternatives. The Company’s areas of focus are epilepsy and schizophrenia.

5 Day Chart for NASDAQ:ZGNX

Receive News & Stock Ratings for Zogenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix Inc. and related stocks with our FREE daily email newsletter.